This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotechrss

Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial

  • Tickers in this article:
  • LXRX

Shares of Lexicon Pharmaceuticals are up nearly 50% since the company announced Monday that its cancer drug telotristat etiprate met its primary goal in a late-stage clinical trial.

08/04/15 - 06:22 PM EDT

Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade

  • Tickers in this article:
  • LXRX

Lexicon Pharmaceuticals (LXRX) shares are up nearly 50% since it announced Monday that its carcinoid syndrome drug telotristat etiprate met its primary endpoint in a late stage clinical trial.

08/04/15 - 05:44 PM EDT

Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial

Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial

  • Tickers in this article:
  • LXRX

Shares of Lexicon Pharmaceuticals are up nearly 50% since the company announced Monday that its cancer drug telotristat etiprate met its primary goal in a late-stage clinical trial.

08/04/15 - 06:22 PM EDT

Ireland's Shire Offers to Acquire Baxter Spinoff for $30.6 Billion

Ireland's Shire Offers to Acquire Baxter Spinoff for $30.6 Billion

Shire makes a bid to buy Baxalta, a specialist in the treatment of rare diseases.

08/04/15 - 05:11 PM EDT

Baxalta Shares Spike Following Shire's $30.6B Takeover Offer

Baxalta Shares Spike Following Shire's $30.6B Takeover Offer

Drug manufacturer Baxalta (BXLT) was the best performing stock in the S&P 500 Tuesday after an unsolicited takeover offer from a competitor. The stock is TheStreet's Move of the Day.

08/04/15 - 05:26 PM EDT

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire Proposes $30B Deal to Buy Disease Specialist Baxalta

Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.

08/04/15 - 01:07 PM EDT

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short

Seven Reasons to Love Biomarin's Duchenne Drug Falls One Short

RBC Capital analyst Michael Yee offers seven reasons why Biomarin Pharmaceuticals will secure U.S. approval for drisapersen to treat Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.

08/04/15 - 11:25 AM EDT

U.S. Stocks Open Flat; Paychex Small Business Survey Shows Growth

U.S. Stocks Open Flat; Paychex Small Business Survey Shows Growth

U.S. stocks opened flat Tuesday. The latest Paychex survey on small business shows steady, continued growth.

08/04/15 - 09:55 AM EDT

Expedia Tops S&P 500; Stocks Slip as Crude Oil Drops 21% in July

Expedia Tops S&P 500; Stocks Slip as Crude Oil Drops 21% in July

Expedia (EXPE) was one of the best performers on the S&P 500 Friday after topping quarterly profit estimates.

07/31/15 - 04:31 PM EDT

Will Teva (TEVA) Stock be Helped by New Financing Commitment?

Will Teva (TEVA) Stock be Helped by New Financing Commitment?

  • Tickers in this article:
  • TEVA

Teva (TEVA) shares are down but the company reported that it has secured $33.75 billion in funding towards its purchase of Allergan's generic drugs business.

07/31/15 - 03:54 PM EDT

Vivus (VVUS) Stock Falls Following Earnings Release, Restructuring Plan

Vivus (VVUS) Stock Falls Following Earnings Release, Restructuring Plan

  • Tickers in this article:
  • VVUS

Vivus (VVUS) shares are down following the the release of the company's second quarter earnings results.

07/31/15 - 03:25 PM EDT

Four Stem-Cell Stocks With Promise

Four Stem-Cell Stocks With Promise

Raymond James analyst Reni Benjamin says positive news may be ahead for these companies.

07/30/15 - 02:19 PM EDT

Thoratec Sale May Be Precursor of More Cardiac Industry M&A

Thoratec Sale May Be Precursor of More Cardiac Industry M&A

With Thoratec Corp. (THOR) off the market following its recent purchase by St. Jude Medical Inc. (STJ), M&A activity may start to circulate in the heart care device sector.

07/30/15 - 01:39 PM EDT

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

Pluristem, Capricor Lead Regenerative Space Says Raymond James Analyst

Fate Therapeutics (FATE) is developing several small molecules which modulate umbilical cord stem cells.

07/30/15 - 12:37 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

Chart of I:DJI
DOW 17,550.69 -47.51 -0.27%
S&P 500 2,093.32 -4.72 -0.22%
NASDAQ 5,105.5460 -9.8360 -0.19%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs